Viemed Healthcare (VMD) Q3 2024 earnings summary

Executive summary

• Net revenue for Q3 2024 reached a record $58 million, up 17.4% year-over-year and 5.5% sequentially, exceeding guidance and driven by organic growth and recent M&A activity.

• Net income increased 33% year-over-year to $3.9 million ($0.10 per diluted share); Adjusted EBITDA rose 15.5% to $14.0 million.

• Employee count surpassed 1,150, reflecting ongoing expansion and operational focus.

• The company differentiates itself with a high-touch, technology-driven home care model, emphasizing patient satisfaction and outcomes.

Financial highlights

• Gross margin was 59.3%, consistent with recent quarters but down year-over-year due to product mix shifts.

• Adjusted EBITDA margin reached 24.1%, up from 23.3% in Q2 and close to 24.5% a year ago.

• Net income for Q3 2024 was $3.9 million, up from $2.9 million in Q3 2023.

• SG&A expenses declined to 46% of revenue, reflecting improved cost controls and operational efficiencies.

• Cash increased by $2.5 million to $11.3 million, and $2 million was paid down on the line of credit.

Outlook and guidance

• Q4 net revenue is projected at $59.7–$60.9 million, implying 4% sequential and 18.9% year-over-year growth.

• Continued sequential growth in vent and sleep patients, with a strong base for organic growth into 2025.

• Adjusted EBITDA is expected to remain solid, with no major changes in margin profile anticipated.

• Improved outlook attributed to sales force restructuring and operational efficiencies.